CDK6 and osteosarcoma: Additionally, about 20–23% of primary osteosarcoma biopsies showed intact Rb protein but defective p16INK4A or CDK4/CDK6 overexpression, indicating that CDK4/CDK6 inhibition could benefit a subset of patients.